Vor Biopharma

Yahoo Finance • 17 days ago

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gross proceeds of $115 million raise... Full story

Yahoo Finance • 19 days ago

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an underwritten public offe... Full story

Yahoo Finance • 22 days ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated a 55% reduction in 24-hour urine protei... Full story

Yahoo Finance • last month

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living (MG-ADL) improveme... Full story

Yahoo Finance • last month

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss... Full story

Yahoo Finance • last month

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in Ch... Full story

Yahoo Finance • 2 months ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 19, 2025, the Compensation Committee... Full story

Yahoo Finance • 2 months ago

After-Hours Movers: Biotech And Medtech Stocks Jump On Volume And News

(RTTNews) - A wave of after-hours activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Belo... Full story

Yahoo Finance • 2 months ago

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating tel... Full story

Yahoo Finance • 2 months ago

Vor Biopharma registers 51M shares for resale linked to RemeGen deal and PIPE financing

* Vor Biopharma (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) has filed a prospectus to register 51M shares of common stock for potential resale by existing stockholders. * Includes: 16M shares issuable under a warrant granted to... Full story

Yahoo Finance • 2 months ago

Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects

[Wall Street,NYC] Lisa-Blue/iStock via Getty Images Vor Biopharma (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prosp... Full story

Yahoo Finance • 2 months ago

Vor Biopharma trading halted on Thursday, news pending

[Reflective keychain with text stop lies on hundred dollar bills, business] Victoria Kotlyarchuk /iStock via Getty Images * Vor Biopharma (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) trading was halted on September 18, 2025, pendi... Full story

Yahoo Finance • 2 months ago

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusi... Full story

Yahoo Finance • 2 months ago

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in Ch... Full story

Yahoo Finance • 3 months ago

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host vi... Full story

Yahoo Finance • 3 months ago

Vor Biopharma shareholders approve equity plan changes and reverse stock split authorization

Vor Biopharma Inc. (NASDAQ:VOR), a biotechnology company currently valued at $263 million, announced Wednesday that its shareholders approved several proposals at a special meeting held Monday, according to a statement based on a recent SE... Full story

Yahoo Finance • 3 months ago

Form 8K Vor Biopharma Inc For: 27 August

... Full story

Yahoo Finance • 4 months ago

Vor Bio, RemeGen succeed in trial for telitacicept in China

[Hand inserts a molecule into DNA.] Natali_Mis/iStock via Getty Images Shares of Vor Bio (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a late stage... Full story

Yahoo Finance • 4 months ago

Telitacicept meets primary endpoint in China's phase 3 Sjögren's trial

CAMBRIDGE, Mass. - Vor Bio (NASDAQ:VOR) announced Wednesday that its collaborator RemeGen Co., Ltd (HKEX:9995, SHA:688331) achieved the primary endpoint in a Phase 3 clinical study of telitacicept for primary Sjögren’s disease in China. Re... Full story

Yahoo Finance • 4 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's dise... Full story